Brief: HLS Says Vascepa Reported To Reduce Coronary Plaque In Evaporate Study Final Results
31/08/2020 11:33
Aug 31 (Reuters) - HLS Therapeutics Inc HLS.TO :
* VASCEPA® (ICOSAPENT ETHYL) REPORTED TO SIGNIFICANTLY
REDUCE
CORONARY PLAQUE IN EVAPORATE STUDY FINAL RESULTS PRESENTED AT
ESC CONGRESS 2020
* HLS THERAPEUTICS INC - PRIMARY ENDPOINT OF SLOWED CORONARY
PLAQUE PROGRESSION REPORTED TO HAVE BEEN MET WITH VASCEPA
Source text for Eikon: ID:nCNWPsZtNa
Further company coverage: HLS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HLS Therapeutics
See all newsCanada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group
Canada's HLS Therapeutics Q1 revenue rises on Vascepa growth, reaffirms 2026 guidance
Canada's HLS Therapeutics Q4 revenue slightly beats on Vascepa strength
Brief: Esperion Partner announces HLS Therapeutics received approval Of NILEMDO for the reduction of LDL-cholesterol in canadians at risk of cardiovascular disease
Brief: HLS Therapeutics announces Health Canada approval of NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease